UK pharmaceuticals business Redx today became the latest firm to unveil plans to delist from the London stock market after the firm bemoaned the low price its shares were trading at.
The Cheshire-based company, which develops treatments for fibrotic disease and cancer, said it would seek shareholder approval to quit the AIM market and re-register as a private company, adding its listed status meant that it was “liquidity constrained”.
